{
  "docId": "019dd923-5f69-752d-a9b6-0d0782a66fef",
  "docSlug": "GU7tHQNbAVEJiBcjPEiK",
  "documentTitle": "See the pitch deck that Compass Pathways used to raise $80 million and fuel its rise into one of the world's biggest psychedelics companies",
  "authorId": "Pitchdecks",
  "authorName": "Compass Pathways",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.333,
  "pageNumber": 2,
  "pageCount": 28,
  "prevPage": 1,
  "nextPage": 3,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 8,
  "notes": null,
  "elementsJson": [
    "bullet_list"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5f69-752d-a9b6-0d0782a66fef/2",
  "deckHref": "/decks/019dd923-5f69-752d-a9b6-0d0782a66fef",
  "deckJsonHref": "/decks/019dd923-5f69-752d-a9b6-0d0782a66fef.json",
  "deckAnchorHref": "/decks/019dd923-5f69-752d-a9b6-0d0782a66fef#slide-2",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.06,
        "y": 0.48
      },
      "kind": "list",
      "text": "REASON TO BELIEVE: We work closely with top scientists, regulators, and technology players. Actively engaged, highly respected advisors and partners from leading institutions.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "11406279-5657-4536-844b-e110674ac350",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.06,
        "y": 0.135
      },
      "kind": "list",
      "text": "OPPORTUNITY: We address society's largest unmet medical need: depression. Annual cost of depression of £300bn in EU and US alone. Initial focus: treatment-resistant depression (TRD), representing 100m patients out of 320m globally.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7ed0679d-76f8-4b79-8ae1-04973f10b48e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.06,
        "y": 0.305
      },
      "kind": "list",
      "text": "A SOLUTION: We are developing psilocybin therapy as safe, superior TRD therapy. Psilocybin therapy likely more efficacious, shorter in time, and at more affordable cost than alternatives.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d2c65af3-aada-4806-9238-396f1fc129d6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.06,
        "y": 0.64
      },
      "kind": "list",
      "text": "UNIT ECONOMICS: We will sell psilocybin therapy to healthcare delivery points, get reimbursed for outcomes. Initial business model allows >50% contribution margin.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "de30478e-43aa-4c47-8a26-a01a62f63f2a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.06,
        "y": 0.79
      },
      "kind": "list",
      "text": "FINANCING: We raised £25m Series A in September 2018 for milestones to H2 2020. Next 18 months: initial results of largest psilocybin clinical trial in history.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f10b9f9b-2f96-4a9c-91e0-a3e379066ff8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "contribution margin: >50%",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd952-9d68-761b-a001-2f3cdf5541ec",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.35,
        "x": 0.06,
        "y": 0.965
      },
      "kind": "source-note",
      "text": "Source: Analysis Group; EMA; Eurostat; FDA; OECD; WHO",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "15523f04-263c-43e0-b349-41df6d821e23",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.28,
        "x": 0.06,
        "y": 0.04
      },
      "kind": "title",
      "text": "Executive Summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6eaf871e-859e-42fb-a397-6abf08848250",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "15f72ebd-03a0-46d9-82c4-23d56b26815b",
      "evidence": "list/bullet: OPPORTUNITY: We address society's largest unmet medical need",
      "confidence": 0.9
    }
  ],
  "frameworks": [
    {
      "name": "executive-summary",
      "slug": null,
      "matchId": "c0fcd9a2-d701-4ac3-a807-38010299e185",
      "evidence": "The slide is titled Executive Summary and provides a structured overview of the business.",
      "confidence": 1
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}